瑞康医药: 关于公司及子公司担保额度预计的公告

Summary of Key Points Core Viewpoint - 瑞康医药集团股份有限公司 has approved a proposal to provide guarantees for its subsidiaries, with a total guarantee limit not exceeding RMB 2 billion, aimed at ensuring smooth operational financing and enhancing management of external guarantees [1][2]. Group 1: Guarantee Overview - The company plans to provide guarantees for its subsidiaries, with a total limit of RMB 2 billion, including a maximum of RMB 1 billion for subsidiaries with a debt-to-asset ratio above 70% [1]. - The guarantees will cover various financing activities such as comprehensive credit applications, loans, and leasing [2]. - The actual guarantee amounts will be determined based on specific agreements and will not require additional board or shareholder meetings for approval within the set limits [2]. Group 2: Financial Risk Management - All guaranteed entities are within the company's consolidated financial statements, and the financial risks are considered manageable [2][3]. - As of the announcement date, the company has provided guarantees totaling RMB 545.20 million, representing 9.85% of the audited net assets attributable to the parent company for 2024 [3]. - The company has no overdue guarantees or any litigation related to guarantees as of the announcement date [3]. Group 3: Board of Directors' Opinion - The board believes that providing guarantees for wholly-owned and controlled subsidiaries is necessary for the company's operations and business development [3]. - The risks associated with these guarantees are deemed controllable, and there is no harm to the interests of the company or its shareholders, particularly minority shareholders [3].